Search

Simple Summary: Sarcomas refer to a broad group of rare tumors that develop from bone and soft tissue. Sarcoma diagnosis is challenging because of its rarity and complexity, leading to misdiagnosis and delays in diagnosis and access to appropriate therapy. Liposarcomas are a common form of sarcoma, and there are four subtypes of liposarcomas: well-differentiated liposarcoma/atypical lipomatous tumors, dedifferentiated liposarcoma, myxoid liposarcoma, and pleomorphic liposarcoma. Treatment options are limited for those diagnosed with liposarcoma. Currently, the mainstay of therapy for primary localized liposarcoma is surgical removal of the tumor. Radiotherapy is commonly used in extremity tumors before surgery but has unproven effectiveness in the retroperitoneum. Chemotherapy sensitivity varies by liposarcoma subtype, further complicating treatment. As such, limited conventional treatment options (e.g., radiotherapy or chemotherapy) remain substantial barriers to care. This review provides information about the epidemiology, pathology, and treatment options currently available for liposarcoma. Sarcomas are a heterogeneous group of neoplasms that develop from bone and soft tissue. Approximately 80% of sarcomas affect soft tissue, with liposarcoma being one of the most common types, accounting for approximately 13–20% of all soft-tissue sarcomas. Per the World Health Organization, liposarcoma can be broadly classified into four different subtypes based on histologic examination: well-differentiated liposarcoma (WDLS)/atypical lipomatous tumors (ALT), dedifferentiated liposarcoma (DDLS), myxoid liposarcoma (MLS), and pleomorphic liposarcoma (PLS). WDLS/ALT is the most common liposarcoma subtype, accounting for approximately 31–33% of liposarcomas; DDLS accounts for 20%; MLS accounts for 19%; and PLS, the least common subtype, represents 7–8% of liposarcomas. Sarcoma diagnosis is challenging because of its rarity, intrinsic complexity, and diagnostic technological complexity. Sarcomas are misdiagnosed in approximately 30% of cases, leading to delays in diagnosis and access to appropriate therapy and clinical trials. Furthermore, treatment options are limited for those diagnosed with liposarcoma. This review discusses the epidemiology, pathology, and treatment options currently available for liposarcoma. [ABSTRACT FROM AUTHOR]